Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Nathanson

Showing results (401-410 of 528) with videos related to

Pageof 53
Sort By:
JAMA Oncology|July 2, 2016
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA MutationsCatherine A Shu, Malcolm C Pike, Anjali R Jotwani, et al.
Breast Cancer Research and Treatment|September 27, 2012
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriersKristen N Stevens, Xianshu Wang, Zachary Fredericksen, et al.
Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.
Nature Genetics|April 23, 2002
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutationsHanne Meijers-Heijboer, Ans van den Ouweland, Jan Klijn, et al.
NPJ Breast Cancer|June 27, 2017
A functionally significant SNP in TP53 and breast cancer risk in African-American womenMaureen E Murphy, Song Liu, Song Yao, et al.
European Journal of Human Genetics : EJHG|August 24, 2018
Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriersLogan C Walker, Louise Marquart, John F Pearson, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerAnton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
NPJ Breast Cancer|September 23, 2020
Association of germline variation with the survival of women with <i>BRCA1/2</i> pathogenic variants and breast cancerTaru A Muranen, Sofia Khan, Rainer Fagerholm, et al.
Cancer Research|July 18, 2020
A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple CancersJacquelyn Powers, Emilia M Pinto, Thibaut Barnoud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, and <i>PALB2</i>Siddhartha Yadav, Nicholas J Boddicker, Jie Na, et al.
Pageof 53

Showing results (401-410 of 528) with videos related to

Sort By:
Pageof 53
JAMA Oncology|July 2, 2016
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA MutationsCatherine A Shu, Malcolm C Pike, Anjali R Jotwani, et al.
Breast Cancer Research and Treatment|September 27, 2012
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriersKristen N Stevens, Xianshu Wang, Zachary Fredericksen, et al.
Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.
Nature Genetics|April 23, 2002
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutationsHanne Meijers-Heijboer, Ans van den Ouweland, Jan Klijn, et al.
NPJ Breast Cancer|June 27, 2017
A functionally significant SNP in TP53 and breast cancer risk in African-American womenMaureen E Murphy, Song Liu, Song Yao, et al.
European Journal of Human Genetics : EJHG|August 24, 2018
Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriersLogan C Walker, Louise Marquart, John F Pearson, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerAnton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
NPJ Breast Cancer|September 23, 2020
Association of germline variation with the survival of women with <i>BRCA1/2</i> pathogenic variants and breast cancerTaru A Muranen, Sofia Khan, Rainer Fagerholm, et al.
Cancer Research|July 18, 2020
A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple CancersJacquelyn Powers, Emilia M Pinto, Thibaut Barnoud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, and <i>PALB2</i>Siddhartha Yadav, Nicholas J Boddicker, Jie Na, et al.
Pageof 53